Business Description
Santen Pharmaceutical Co Ltd
ISIN : JP3336000009
Share Class Description:
MEX:4536N: Ordinary SharesTotal Employee Number:
3,849Description
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company provides a wide range of prescription and over-the-counter eye care products, including treatments for glaucoma, dry eye, and allergies. It also develops surgical and diagnostic devices related to eye care.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.72 | |||||
Interest Coverage | 24.38 | |||||
Piotroski F-Score | 9/9 | |||||
Altman Z-Score | 5.48 | |||||
Beneish M-Score | -2.57 | |||||
WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 7.2 | |||||
3-Year EBITDA Growth Rate | 83.5 | |||||
3-Year FCF Growth Rate | 40 | |||||
3-Year Book Growth Rate | 5.7 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.82 | |||||
Quick Ratio | 1.98 | |||||
Cash Ratio | 1.04 | |||||
Days Inventory | 188.73 | |||||
Days Sales Outstanding | 83.49 | |||||
Days Payable | 103.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Payout Ratio | 0.33 | |||||
3-Year Dividend Growth Rate | 5.9 | |||||
3-Year Average Share Buyback Ratio | 5 | |||||
Shareholder Yield % | 6.07 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 59.15 | |||||
Operating Margin % | 16.56 | |||||
Net Margin % | 13.26 | |||||
EBITDA Margin % | 20.32 | |||||
FCF Margin % | 9.19 | |||||
OCF Margin % | 13.95 | |||||
ROE % | 13.46 | |||||
ROA % | 9.49 | |||||
ROIC % | 13.21 | |||||
3-Year ROIIC % | -371.63 | |||||
ROC (Joel Greenblatt) % | 37.72 | |||||
ROCE % | 15.38 | |||||
Years of Profitability over Past 10-Year | 9 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 16.35 | |||||
Forward PE Ratio | 26.11 | |||||
PE Ratio without NRI | 16.35 | |||||
Shiller PE Ratio | 28.66 | |||||
Price-to-Owner-Earnings | 17.85 | |||||
PEG Ratio | 0.73 | |||||
PS Ratio | 2.19 | |||||
PB Ratio | 2.09 | |||||
Price-to-Tangible-Book | 2.74 | |||||
Price-to-Free-Cash-Flow | 23 | |||||
Price-to-Operating-Cash-Flow | 15.57 | |||||
EV-to-EBIT | 10.78 | |||||
EV-to-Forward-EBIT | 12.39 | |||||
EV-to-EBITDA | 9.15 | |||||
EV-to-Forward-EBITDA | 11.38 | |||||
EV-to-Revenue | 1.86 | |||||
EV-to-Forward-Revenue | 2.71 | |||||
EV-to-FCF | 19.6 | |||||
Price-to-GF-Value | 1.13 | |||||
Price-to-Projected-FCF | 1.21 | |||||
Price-to-Median-PS-Value | 0.9 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.67 | |||||
Price-to-Graham-Number | 1.41 | |||||
| Price-to-Net-Current-Asset-Value | 6.01 | |||||
Earnings Yield (Greenblatt) % | 9.28 | |||||
FCF Yield % | 4.43 | |||||
Forward Rate of Return (Yacktman) % | 24.2 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Santen Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 33,597.683 | ||
| EPS (TTM) (MXN) | 13.632 | ||
| Beta | 0.0002 | ||
| 3-Year Sharpe Ratio | -72.66 | ||
| 3-Year Sortino Ratio | -3.46 | ||
| Volatility % | 0.9 | ||
| 14-Day RSI | - | ||
| 14-Day ATR (MXN) | - | ||
| 20-Day SMA (MXN) | 339.23 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (MXN) | 339.23 - 339.23 | ||
| Shares Outstanding (Mil) | 321.69 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Santen Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Santen Pharmaceutical Co Ltd Stock Events
| Event | Date | Price (MXN) | ||
|---|---|---|---|---|
| JPY 21.000000 Cash Dividend | 2026-09-30 | In 49 days | ||
| JPY 19.000000 Cash Dividend | 2026-03-31 | 339.23 (+0.00%) | ||
| JPY 19.000000 Cash Dividend | 2025-09-30 | 339.23 (+0.00%) | ||
| JPY 19.000000 Cash Dividend | 2025-03-31 | 339.23 (+0.00%) | ||
| JPY 17.000000 Cash Dividend | 2024-09-30 | 339.23 (+0.00%) |
Show
Entries
Santen Pharmaceutical Co Ltd Frequently Asked Questions
What is Santen Pharmaceutical Co Ltd(MEX:4536N)'s stock price today?
The current price of MEX:4536N is MXN339.23. The 52 week high of MEX:4536N is MXN339.23 and 52 week low is MXN339.23.
When is next earnings date of Santen Pharmaceutical Co Ltd(MEX:4536N)?
The next earnings date of Santen Pharmaceutical Co Ltd(MEX:4536N) is .
Does Santen Pharmaceutical Co Ltd(MEX:4536N) pay dividends? If so, how much?
Santen Pharmaceutical Co Ltd(MEX:4536N) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Santen Pharmaceutical Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers